Roche, Prothena ink potential $600 million deal for Parkinson's disease

Drug giant Roche will pay Elan Corp. offshoot Prothena Corp. plc $45 million upfront as they work together on antibodies targeting Parkinson's disease...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.